Navigation Links
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Date:9/11/2007

s trial which could expand the application into the larger indolent NHL market."

Pixantrone in Indolent NHL

Preliminary results from a phase I/II study of pixantrone combined with fludarabine, dexamethasone, and rituximab for patients with relapsed indolent NHL were presented at the American Society of Hematology (ASH) annual meeting in December 2006. Among the 27 patients evaluable for response, study results showed the FPD-R regimen with pixantrone produced an 89 percent overall response rate (ORR) by the Cheson criteria, including 70 percent of patients experiencing a complete response/unconfirmed complete response (CR/uCR; 63 percent, CR and seven percent, u/CR). The estimated median duration of response was 25 months and the estimated progression-free survival rate at three years was 50.4 percent.

In addition, pixantrone was studied in a randomized clinical trial for indolent NHL patients comparing pixantrone in combination with rituximab to rituximab alone, with time to progression (TTP) as the primary efficacy endpoint. The study of 38 relapsed or refractory patients receiving the combination of rituximab and pixantrone had a 60 percent overall improvement in TTP compared to rituximab alone. [SC1] The median TTP estimate for the pixantrone/rituximab recipients was 13.0 months compared to 8.1 months for rituximab alone (hazard ratio 0.13, log rank p<0.001).

Pixantrone in Aggressive NHL

Pixantrone is the subject of two ongoing studies in aggressive NHL, a phase III single agent trial, known as EXTEND (PIX301) and a phase II/III combination study, known as RAPID (PIX203). The EXTEND trial explores the role of single agent treatment as a salvage regimen in patients with relapsed aggressive NHL who have failed at least two prior treatment regimens. Patients are randomized to receive either pixantrone or another single-agent drug of physician's choice currently used for the treatment of this patient population.

The RAPID trial is
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Oct. 1, 2014  Dyadic International, Inc. ("Dyadic") ... and proprietary technology used to develop and produce ... chemicals, biopharmaceuticals, and industrial enzymes industries, today announced ... Abengoa Bioenergy for commercial scale production of Abengoa,s ... ethanol, developed under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... and NEW YORK , October 1, ... Research Organization (CRO) and service provider for the medical industries, announced ... of offices in New York City . genae ... City is strategically centered in one of the highest ... Coast", said Philippe Kassab , President at genae Americas. "The ...
(Date:10/1/2014)... ALTO, Calif. , Oct. 1, 2014  Varian ... that it will report results for the fourth quarter ... trading on Wednesday, October 22, 2014.  The news release ... interested parties at 2:00 p.m. PT.  The news release ... be available on the company website at: www.varian.com/investor ...
Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3genae Opens Offices in New York City 2Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
... March 29, 2011 Konica Minolta Sensing Americas, Inc. ... color, light and shape, announces the launch of its ... the pharmaceutical industry at the 2011 Interphex show March ... Center. (Photo: http://photos.prnewswire.com/prnh/20100714/NY35146 ) ...
... March 29, 2011 SinoFresh® HealthCare, Inc., (Pink Sheets: ... signed contracts with three high volume sales agencies. These ... boost to long term sales and distribution along the ... SinoFresh,s Antiseptic Homeopathic Nasal and Sinus Care Spray available ...
Cached Medicine Technology:Konica Minolta Sensing Announces CM-5 Spectrophotometer to Pharmaceutical Industry at Interphex 2011 2Konica Minolta Sensing Announces CM-5 Spectrophotometer to Pharmaceutical Industry at Interphex 2011 3SinoFresh HealthCare Signs Three Sale Marketing Agreements 2SinoFresh HealthCare Signs Three Sale Marketing Agreements 3
(Date:10/1/2014)... October 01, 2014 Lifeinsurance-policy.com has ... the best life insurance prices for smokers. , Smoking ... insurance premiums. Comparing quotes is the best method to ... quotes for customers who need coverage. , Whole ... duration of the policy. Since the coverage is permanent, ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Farmington ... including a redefined mission and visual identity helping ... of partnering with them to create greater benefit ... brand that focuses on empowering customers to better ... , The crown jewel of the rebrand is ...
(Date:10/1/2014)... Between 23 million and 50 million people ... figures from the National Institutes of Health (NIH) and ... of them have something else in common: They have ... Gluten Free Therapeutics, makers of CeliVites nutritional ... by publishing a series of blog posts aimed at ...
(Date:10/1/2014)... Anti Aging Clinic (AntiAgingClinic.ca), the Greater ... of choice, is announcing a discounted cost on Botox ... , “We’re doing this because we want to give ... skin clinic in Toronto,” says Dr. Brian Sieber, founder ... Anti Aging Clinic, including laser facials, genesis laser facials, ...
(Date:10/1/2014)... California (PRWEB) October 01, 2014 ... to benefit a very special cause. The campaign—“Buy ... support for Paws for Veterans, a nonprofit organization ... while also rescuing shelter dogs that would otherwise ... of featured products will support monthly donations of ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2
... LAUREL, N.J., July 1 MedQuist Inc.,(Pink ... community hospital,located in Westfield, Mass., has selected ... to provide hospital-wide,dictation, transcription and speech recognition ... recognition capability will be,used throughout the hospital ...
... and Bruce Bradley (General,Motors) - to Serve as ... ABIM Foundation,will dedicate its efforts over the next ... and accountability in health care toward the,ultimate goal ... Foundation announced that officers of its Board of,Trustees ...
... WALTHAM, Mass., July 1 Repligen Corporation,(Nasdaq: RGEN ... has been,elected to its Board of Directors. Dr. Goldberg ... School. He is a renowned scientist noted in,particular for ... the mechanism by which most proteins are destroyed in,cells. ...
... fed junk food had higher cholesterol, blood fats into ... News) -- Eating an unhealthy diet during pregnancy may ... cholesterol and blood sugar levels, British researchers report. , ... fed one group of females a diet of processed ...
... Advantages in Efficacy and Safety Will Make Liraglutide the New Clinical ... ... Resources, WALTHAM, Mass., July 1 ... on pharmaceutical and,healthcare issues, finds that a weight neutral oral antidiabetic drug ...
... Health Administrator, Meet Aggressive Hospital Opening Schedule; Eases Ongoing IT ... ... Effort, RIOJA, Spain, July 1 TIBCO Software Inc.,(Nasdaq: ... region of Rioja has deployed its real-time integration,infrastructure. The project at ...
Cached Medicine News:Health News:Award-Winning Massachusetts Hospital Selects MedQuist Enterprise Technology for Clinical Documentation and Speech Recognition 2Health News:Award-Winning Massachusetts Hospital Selects MedQuist Enterprise Technology for Clinical Documentation and Speech Recognition 3Health News:ABIM Foundation Announces New Focus and Governance 2Health News:ABIM Foundation Announces New Focus and Governance 3Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 2Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 3Health News:Mom's Unhealthy Diet May Have Long-Term Impact on Baby 2Health News:A Weight Neutral Oral Antidiabetic Drug Would Earn a 25 Percent Patient Share in the Type 2 Diabetes Drug Market 2Health News:Rioja Hospital Uses TIBCO Software to Improve Customer Care and Streamline Operations 2
... femoral option and tibial insert which provides a ... degrees of flexion to induce a smooth stable ... of flexion. Femoral component comes in a PS ... constrained tibial insert in conjunction with the femur ...
... True to its leadership role within the ... clinical experience of the industry's leading fixed-bearing ... Knee System, with the clinically proven technology ... leading rotating platform knee. ,The result is ...
... The Femoral component of ... soft tissue and bony destruction ... a high rate of long ... for minimum bone resection and ...
... Knee System is taking total knee replacement to ... of clinical experience. One thing has become clear ... several choices for their patients. Surgeon choice ... factor in long-term patient satisfaction. Biomet responded to ...
Medicine Products: